Innovation Hand in Hand, Shaping the Future Together: Gaobo Healthcare Group and Qitan Technology Announce Strategic Partnership

On September 8, at the opening ceremony of the Gaobo Medical Forum · The 4th Shanghai Symposium on Clinical Applications of Autologous Hematopoietic Stem Cell Transplantation,Gaobo Medical Group and QitanTech Announce Strategic PartnershipBoth parties will focus onThe Demand for Precision Diagnosis and Treatment in Patients with Hematologic Diseases,Leveraging Gaobo Medical Group’s clinically driven innovative technology platform and QitanTech’s leading advantages in next-generation gene sequencing technologies globally, in the areas of disease diagnosis and treatment, scientific research, translation of achievements, talent development, and professional exchangeAchieve in-depth collaboration, join forces to overcome challenges in clinical diagnosis and treatment, jointly advance the development of precision diagnosis and treatment for hematologic diseases, and bring hope to more patients with blood disorders.

 Site of the Strategic Cooperation Signing Ceremony Between Gaobo Medical Group and QitanTech

Mr. Xu Feng, Chief Financial Officer of Gaobo Medical Group; Mr. Bai Jingwei, Co-founder & Chief Scientist of QitanTechDelivered remarks on behalf of both parties. In the presence of clinical experts, diagnostic specialists, and industry peers attending the event,Ms. Zhou Xuan, Executive Dean of Shanghai Zhaxin Hospital/Liquan Hospital under Gaobo Medical Group; Mr. Lin Jianxun, Vice President of QitanTechSigned the strategic cooperation agreement on behalf of both parties.

Ms. Zhou Xuan, Mr. Lin Jianxun

Mr. Xu FengIt was stated that, as a medical service and technological innovation platform dedicated to integrating “medical care, industry, and research,” Gaobo Medical Group has been continuously deepening its expertise in specialized fields such as hematological disorders and oncology. The group aims to leverage its abundant clinical resources and strengths in clinical research to facilitate the optimization of diagnostic and therapeutic practices driven by clinical needs and led by technological innovation. It is believed that through the establishment of a strategic partnership with QitanTech, both parties will be able to fully capitalize on their respective advantages in the health sector, actively promote the clinical translation, implementation, and widespread adoption of next-generation sequencing technologies represented by nanopore sequencing, comprehensively empower various stages of clinical practice and clinical research in hematology, and better meet the diverse health needs of patients with hematological disorders.

Mr. Xu Feng

Mr. Bai JingweiIt was stated that, as a pioneer of domestically produced nanopore sequencing technology, QitanTech has resolved the critical “chokehold” dilemma in key life science technologies and achieved independent control over next-generation gene sequencing technology. It is believed that, with the strong support of Gaobo Medical Group’s extensive clinical experience and outstanding talent pool, both parties will fully leverage the core advantages of nanopore sequencing technology—namely its long read lengths, speed, broad applicability, accuracy, and flexibility—to significantly enhance diagnostic and therapeutic precision as well as research efficiency, thereby providing more efficient, precise, and personalized clinical diagnosis, treatment, and health management services for patients with hematologic disorders.

 Mr. Bai Jingwei

Infection is a clinical challenge faced by every patient with hematologic disorders and every hematologist. The accuracy of diagnosis and the timeliness of management directly impact patient prognosis. Traditional pathogen detection techniques, which cover a limited range of microorganisms, have long reporting cycles, and stringent sample requirements, can no longer adequately meet clinical needs. The signing of this strategic partnership marks a substantive advancement in collaboration between both parties in the fields of personalized therapy and precision medicine for hematologic diseases, laying a solid foundation for higher-quality, more efficient precision diagnosis, treatment, and clinical research. Moving forward, the two parties will leverage precision testing as an entry point to strengthen integrated industry-academia-research cooperation, accelerate the exploration of new paradigms in precision diagnosis and treatment, enhance the quality of medical services, promote the development of the biopharmaceutical industry, and contribute to the Healthy China initiative.

Gaobo Medical Group has always adhered to the philosophy of “Patients’ Needs First,” with the mission and vision of pursuing excellence in diagnosis and treatment, breaking through with innovative technologies, and creating possibilities for life. It is committed to building a clinically driven, innovative medical technology platform. Established in 2017, the Group focuses on clinical care, clinical research, reference laboratories, and health informatics. Currently, it operates seven hospitals in Beijing, Shanghai, and Guangzhou, with a total of nearly 1,500 open beds. The Group specializes in dynamically innovative fields such as solid tumors, hematological diseases, and brain science. It has established professional service sectors including Phase I clinical trial wards, central laboratories, early-phase clinical research centers, clinical pharmacology, medical affairs, and biostatistics. With the medical mission of conquering complex and critical illnesses, Gaobo strives to bring more treatment options and hope to patients suffering from these conditions. Upholding the scientific mission of advancing medical innovation, Gaobo has cumulatively supported hundreds of clinical trials of innovative drugs for hundreds of pharmaceutical companies. Medicine progresses by encouraging innovation, and innovation shines by embracing medicine.

QitanTech, with the mission of “making life’s information accessible,” is a high-tech enterprise that independently developed and launched China’s first and the world’s second commercial nanopore gene sequencing platform, committed to leading a new era in gene sequencing. Established in 2016, the company has been recognized as a National Specialized, Refined, Differential, and Innovative “Little Giant” Enterprise. In December 2021, QitanTech released QNome-3841, China’s first commercial nanopore gene sequencer, successfully bridging the “last mile” in translating R&D achievements into practical applications and ushering in an era of domestically produced nanopore gene sequencing. The company has since launched two major nanopore sequencing platforms, QNome and QPursue, along with multiple end-to-end product solutions. These are widely applied in diverse scenarios such as pathogen research, genetic disease testing, cancer detection, animal disease prevention and control, forensic investigation, and public health epidemic prevention, serving over 200 institutional users to date.